liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Real-world evidence on second line chemotherapy in advanced biliary tract carcinoma refractory to gemcitabine and oxaliplatin (GemOx)
Linköping University, Department of Biomedical and Clinical Sciences, Division of Surgery, Orthopedics and Oncology. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Diagnostics, Department of Clinical Chemistry.ORCID iD: 0009-0005-9335-1807
Linköping University, Department of Biomedical and Clinical Sciences, Division of Surgery, Orthopedics and Oncology. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Diagnostics, Clinical pathology.ORCID iD: 0000-0002-9845-1410
Clin Dept Oncol Kalmar, Sweden.
Linköping University, Department of Biomedical and Clinical Sciences, Division of Surgery, Orthopedics and Oncology. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Oncology.
2026 (English)In: BMC Cancer, E-ISSN 1471-2407, Vol. 26, no 1, article id 496Article in journal (Refereed) Published
Abstract [en]

Background Advanced biliary tract carcinoma (aBTC) comes with poor prognosis. Gemcitabine with oxaliplatin (GemOx) has emerged as a pragmatic alternative to gemcitabine with cisplatin and has been a preferred first line palliative option at many centres around the world.The evidence on second line chemotherapy following treatment failure of GemOx is scarce. Methods A retrospective multicentre cohort study in the Southeast healthcare region of Sweden, covering nine years (2011-2020) and three hospitals, was conducted. All patients with aBTC who had received first line GemOx and any second line treatment thereafter were included.Treatment patterns and clinicopathological prognostic parameters were explored. Results In a cohort of 121 patients with aBTC who had received GemOx in the first line setting, 57 (47%) had proceeded to any type of second line systemic therapy and were included in this study. The most used regimen was capecitabine single agent in 37 (64.9%) patients followed by intravenous 5-FU (9, 15.8%). Median overall survival (OS) in the total cohort was 4.1 months (95% CI 3.2-5.0). Six-and twelve-month survival rates were 35.6% and 18.6%. Median time to treatment failure (TTF) was 1.8 months (95% CI 1.5-2.2). Performance status (PS) 2, according to Eastern Cooperative Oncology Group (ECOG), was an independent predictor for poor OS and TTF. Progression free survival (PFS) of < 6 months during first line treatment and extrahepatic localisation were independent predictors for poor OS. A nomogram was established using ECOG PS, 1st line PFS and primary tumour site. An exploratory prognostic model showed that patients with high total score in the nomogram had OS of 2.9 months compared to 4.3 months in patients with intermediate score and 13.1 months in patients with low score. Conclusion Patients with aBTC receiving second line chemotherapy following first line GemOx have very dismal prognosis. PS 0-1, first line PFS >= 6 months and intrahepatic disease localisation indicate better prognosis. These data highlight the need for improved and personalised treatment strategies in refractory aBTC.

Place, publisher, year, edition, pages
BMC , 2026. Vol. 26, no 1, article id 496
Keywords [en]
Biliary tract neoplasm; Chemotherapy; Second line treatment; Gemcitabine; Oxaliplatin; Palliative care; Real-world evidence; Capecitabine
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-223316DOI: 10.1186/s12885-026-16009-yISI: 001743618600001PubMedID: 41998525Scopus ID: 2-s2.0-105036096603OAI: oai:DiVA.org:liu-223316DiVA, id: diva2:2056093
Note

Funding Agencies|Linkping University

Available from: 2026-04-28 Created: 2026-04-28 Last updated: 2026-06-27

Open Access in DiVA

fulltext(1443 kB)19 downloads
File information
File name FULLTEXT01.pdfFile size 1443 kBChecksum SHA-512
8d487d777cb0b8da2abbf2d27d4bf46af3c5bb4da06643c9409dec828d0c7e88f8ead16916ea201ccdb7afedf273d3c69aacf42964ab5feae0ce8bb679589f55
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Lagenfelt, HannaBlomstrand, HakonElander, Nils
By organisation
Division of Surgery, Orthopedics and OncologyFaculty of Medicine and Health SciencesDepartment of Clinical ChemistryClinical pathologyDepartment of Oncology
In the same journal
BMC Cancer
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 19 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 45 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf